(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.83%) $83.15
(-1.16%) $1.619
(-0.43%) $2 337.10
(0.97%) $27.52
(0.66%) $928.20
(-0.16%) $0.933
(-0.12%) $11.01
(-0.22%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States...
Stats | |
---|---|
本日の出来高 | 199 489 |
平均出来高 | 58 335.00 |
時価総額 | 57.61M |
EPS | $0 ( 2024-03-28 ) |
次の収益日 | ( $-1.500 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.43 |
ATR14 | $0.0870 (0.69%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Ward Shane | Buy | 120 000 | Common Stock |
2024-03-15 | Ward Shane | Buy | 250 000 | Employee Stock Option (right to buy) |
2024-03-15 | Shah Preetam | Buy | 108 750 | Common Stock |
2024-03-15 | Shah Preetam | Buy | 217 500 | Employee Stock Option (right to buy) |
2024-03-15 | Tari Leslie | Buy | 111 250 | Common Stock |
INSIDER POWER |
---|
89.46 |
Last 100 transactions |
Buy: 7 175 633 | Sell: 576 273 |
ボリューム 相関
Cidara Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
NTUS | -0.89 |
DVCR | -0.876 |
OPNT | -0.869 |
JJSF | -0.867 |
SVOK | -0.866 |
LMNX | -0.861 |
PROC | -0.856 |
STAY | -0.852 |
DSPG | -0.843 |
MSON | -0.842 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cidara Therapeutics Inc 相関 - 通貨/商品
Cidara Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $63.91M |
総利益: | $62.38M (97.62 %) |
EPS: | $-0.260 |
FY | 2023 |
収益: | $63.91M |
総利益: | $62.38M (97.62 %) |
EPS: | $-0.260 |
FY | 2022 |
収益: | $64.29M |
総利益: | $64.15M (99.78 %) |
EPS: | $-0.430 |
FY | 2021 |
収益: | $49.57M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.810 |
Financial Reports:
No articles found.
Cidara Therapeutics Inc
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。